PI: OHR-1 3/4/2016
Study Title: 4 of 4
OFFICE OF HUMAN RESEARCH OHR-1 (3/4/2016)
Office of Human Research/IRB
PROPOSAL TRANSMITTAL AND APPROVAL FORM
1. PROPOSAL DETAILS:
PRINCIPAL INVESTIGATOR: Dept/Div:
Tel: Fax: Email:
STUDY TITLE:
INDEPENDENT IRB REVIEW
Check here if you are applying for independent IRB review: / Western IRB (WIRB) / Quorum Review IRBFUNDING (Please check all that apply)
Departmental Funds Only / Grant (provide name of granting entity, i.e., American Cancer Society, Damon Runyon Fund, etc.):Departmental with Partial Funding from Commercial Entity (in the form of funding and/or drug or device)
Name of Entity Providing Funds: / NIH. Specify institute:
Commercial Sponsor of Multicenter Clinical Trial
Sponsor: / Commonwealth of PA
Other (please identify entity): / Department of Defense (contact OHR before submission)
ORA ACCOUNT NUMBER (if applicable): ______
GRANTEE (If subcontract to TJU ):
SPONSOR CONTACT PERSON (For-Profit):
Tel: Fax: Email:
TJU CONTACT:
Tel: Fax: Email:
Please be reminded that a sponsored study may not begin until the sponsored agreement is fully executed by the sponsor and Thomas Jefferson University. Contact the Office of Research Administration for more information.
2. HOW TO SUBMIT A NEW STUDY:
· Consult the Overview of IRB Submissions for New Studies to determine level of IRB review and forms & number of copies to submit for your study.
· You must create your study record in JeffTrial and upload your documents to the Portal for your study to be scheduled for IRB review. (For WIRB & Quorum Review IRB submissions, upload OHR-1 only.)
· For instructions on how to use JeffTrial to create study records and notate transactions, access the JeffTrial training manuals for oncology and non-oncology research at http://www.jefferson.edu/university/human_research/irb/jeffTrial/training.html
· For instructions on how to upload documents to the Portal, access the Portal training manual at How To Use The Portal
· Consult http://www.jefferson.edu/university/human_research/irb/using-a-central-irb.html if submitting to Quorum or WIRB
· If study is FDA-regulated please submit a copy of the IND or IDE letter
· If the study involves a drug/device that is not investigational, include one copy of the package insert or device brochure.
3. AUTHORIZATIONS:
EMERGENCY DEPARTMENT APPROVAL
[ ] If your study involves human subjects from the Emergency Department (ED), please certify that the ED has been notified, and attach a copy of the ED letter of acknowledgement. YOU MAY NOT SUBMIT TO THE IRB UNTIL YOU HAVE THIS LETTER. Contact the ED at 955-1993 for more information.
ECHOCARDIOGRAPHY APPROVAL
[ ] If your study involves echocardiography, please certify that the protocol has been reviewed by the ECHOCARDIOGRAPHY LAB and include the approval letter with your submission. YOU MAY NOT SUBMIT TO THE IRB UNTIL YOU HAVE THIS LETTER. Contact the Director of the Echocardiography Lab at 955-7100 for more information.
RADIOLOGY APPROVAL
[ ] If your study involves CT, MR and/or PET scanning for research purposes, please certify that the protocol has been reviewed and approved by the Radiology Dept. and include the approval letter with your submission. YOU MAY NOT SUBMIT TO THE IRB UNTIL YOU HAVE THIS APPROVAL. Submit your request using the link on the forms page of the IRB website. You may also contact Janet Kott at 215-955-5900 or ’
CCRRC APPROVAL / ALL CANCER-RELATED RESEARCH
1. Does the scope of your research involve cancer (patients, tissue, data, blood, charts, etc.)?
[ ] YES [ ] NO
2. If you marked “YES” for question 1, please certify that the KCC Protocol Coversheet has been completed and submitted to the CCRRC (Clinical Cancer Research Review Committee).
[ ] YES [ ] NO
3. Please also confirm that your trial has been approved by the CCRRC or has been given a waiver from CCRRC review. Also please include a copy of the CCRRC approval or waiver email in the IRB submission.
[ ] YES [ ] NO
- Is the CRMO acting as the administrative support office for this study?
[ ] YES [ ] NO
YOU MAY NOT SUBMIT TO THE IRB UNTIL YOU HAVE CCRRC APPROVAL or WAIVER. Contact the CRMO at 955-3698 for more information.
RADIATION SAFETY COMMITTEE APPROVAL
[ ] If your study involves radiation exposure greater than that of standard of care, please submit form OHR-32 to the Radiation Safety Officer (John Keklak at 5-1950 or .
INSTITUTIONAL BIOSAFETY COMMITTEE AND IRB REVIEW AND APPROVAL
[ ] If your study is interventional and involves recombinant DNA technology (gene therapy or gene transfer) please contact Sue Gotta in Environmental Health and Safety at 3-7422 or AND the IRB prior to study submission.
NURSING DEPARTMENT APPROVAL
[ ] If your study involves Nursing Department personnel in any role or requires nurses to add to or alter their patient care and/or documentation practices, please certify that the project has been reviewed by the Department of Nursing's Office of Nursing Research and attach a letter of acknowledgment. YOU MAY NOT SUBMIT TO THE IRB UNTIL YOU HAVE THIS LETTER. Contact the Office of Nursing Research at 503-6122 for more information.
4. CERTIFICATION OF CONFLICTS OF INTEREST:
See TJU Policy 107.03, Conflicts of Interests for Employees” attachment 2 for more detailed information
THIS CERTIFICATION MUST BE COMPLETED AND ALL THE REQUIRED SIGNATURES MUST BE OBTAINED BEFORE THIS PROTOCOL/RESEARCH PROJECT MAY BE ADMINISTRATIVELY PROCESSED.
Each Investigator and all Key Personnel must answer the following questions in relation to this proposal.
Principal and Co-Investigators & Key Personnel:
Copy this section as necessary to accommodate all personnel on study.
This study personnel is (check appropriate box): TJU TJUH JUP student volunteer contract staff other
Name:______
1. Do you have a current Conflicts of Interest Disclosure on file with the University?
_____Yes
_____No
_____Not Sure
2. Do you or an immediate family member have any financial interests as defined in the TJU Conflicts of Interest Policy 107.03?
_____Yes
_____No
3. Do you or an immediate family member have a significant financial interest that may pose a conflict of interest as defined in the TJU Conflicts of Interest Policy 107.03?
_____Yes
_____No
If you checked “yes” to question 2 or 3 above, describe the financial interest below and any steps planned to prevent the financial interest from interfering with the design, conduct, or reporting of the research, including interfering with the protection of participants. Attach separate sheet if needed.
Check appropriate boxes in the table below.
Significant financial interest in the sponsor or subcontractor, i.e., paid consultancy, stock, stock options, ownership, etc.Intellectual property rights (patents, pending patents, copyrights, trademarks, licensing agreement, royalties)
Honoraria, speaker’s fees, paid authorship
Gifts
Trips
Service on Board
Paid expert testimony
Compensation for employment (by other than TJU/TJUH)
Other
None
How do you plan to manage the conflict?
Reduce ______Manage _____ Eliminate _____
If you identified a potential conflict of interest on this form that is not known to the TJU COI Committee, contact Janyce Lingo at 215-503-0758 or .
If you are a TJU employee or faculty member, or a TJUH employee you must have submitted an up-to-date Disclosure of Conflicts of Interest to University Counsel. If you have not, please complete an on-line Disclosure that can be accessed via the Pulse homepage or a hard copy that may be obtained on the Office of University Counsel website. If you are not a TJU employee, TJUH employee, nor a TJU faculty member, you must file a Disclosure Statement for Non TJU/TJUH Employees Conducting Research indicating either the nature of the conflict of interest, if any, or certifying that you do not have a conflict of interest in a financially interested company with regard to this proposal.
RELATIONSHIP(S) WITH OTHER ENTITIES
The Principal Investigator must complete the following:
Other than the entity paying for the study or as disclosed in the protocol, will any OTHER ENTITY(S):
1. Require and/or receive reports or other information regarding this study? [ ] Yes [ ] No
If yes, list entity (s) ______
2. Be identified in any reports submitted to the FDA or other regulatory agencies? [ ] Yes [ ] No
If yes, list entity(s) ______
3. Be given access to study data? [ ] Yes [ ] No
If yes, list entity(s) ______
4. Be given attribution in any publication or presentation regarding this study? [ ] Yes [ ] No
If yes, list entity(s) ______
The IRB must be notified in writing by the PI should any of the answers to the above change.
5. SIGNATURES:
The OHR-1 must be signed by the Principal Investigator, and the Chair and Business Administrator of his/her department. All other investigators and research personnel on the study must be listed below. Signatures for these personnel are not required. However, if personnel from a department other than that of the PI are involved in the study, the chair and business administrator of that department also must sign below.
· The Principal Investigator agrees to accept responsibility for the conduct of the project according to the tenets of Good Clinical Practice (OHR Policy GA 124, “Good Clinical Practice for Investigators”) and to provide the required progress reports if a grant/contract results from application/proposal.
· Department Chairs certify that the project meets Departmental standards with respect to scientific validity and that the project is consistent with Departmental goals.
· Administrators certify that the project meets applicable federal fiduciary requirements.
Principal Investigator / Departmental Chair / Business AdministratorSign above and print name here / Sign above and print name here / Sign above and print name here
Co-Investigators/Key Personnel
(List names below – signatures not req’d) / Departmental Chair
(Signature required if department differs from that of PI) / Business Administrator
(Signature required if department differs from that of PI)